# Prevalence of the Mutational Status of V-Ki-ras2 Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) in Metastatic Colorectal Cancer (mCRC) in Argentine Patients

> **NCT01082757** · — · COMPLETED · sponsor: **Merck KGaA, Darmstadt, Germany** · enrollment: 1524 (actual)

## Conditions studied

- Colorectal Neoplasms

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT01082757
- **Lead sponsor:** Merck KGaA, Darmstadt, Germany
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2009-06
- **Primary completion:** 2013-08
- **Final completion:** 2013-08
- **Target enrollment:** 1524 (ACTUAL)
- **Last updated:** 2014-07-31

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01082757

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01082757, "Prevalence of the Mutational Status of V-Ki-ras2 Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) in Metastatic Colorectal Cancer (mCRC) in Argentine Patients". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT01082757. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*